IP Library Granted Patent US 7,915,265
Granted Patent B2
US 7,915,265 · App. 11/354,552 · Granted Mar 29, 2011

Combinations for the treatment of immunoinflammatory disorders

Assignee: Zalicus Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,915,265
App. No.
11/354,552
Granted
Mar 29, 2011
Kind
B2
Abstract

The invention features pharmaceutical compositions that include dipyridamole and a corticosteroid.

Claims (13)

1. A pharmaceutical composition comprising only two active ingredients wherein the first of said active ingredients is a corticosteroid and the second of said active ingredients is dipyridamole, wherein said composition comprises 0.5 to 10 mg corticosteroid and 100 to 400 mg of dipyridamole, wherein said dipyridamole enhances the potency of said corticosteroid and wherein said pharmaceutical composition further comprises an excipient.

2. The composition of claim 1 , wherein said corticosteroid is algestone, 6-alpha-fluoroprednisolone, 6-alpha-methylprednisolone, 6-alpha-methylprednisolone 21-acetate, 6-alpha-methylprednisolone 21-hemisuccinate sodium salt, 6-alpha,9-alpha-difluoroprednisolone 21-acetate 17-butyrate, amcinafal, beclomethasone, beclomethasone dipropionate, beclomethasone dipropionate monohydrate, 6-beta-hydroxycortisol, betamethasone, betamethasone-17-valerate, budesonide, clobetasol, clobetasol propionate, clobetasone, clocortolone, clocortolone pivalate, cortisone, cortisone acetate, cortodoxone, deflazacort, 21-deoxycortisol, deprodone, descinolone, desonide, desoximethasone, dexamethasone, dexamethasone-21-acetate, dichlorisone, diflorasone, diflorasone diacetate, diflucortolone, doxibetasol, fludrocortisone, flumethasone, flumethasone pivalate, flumoxonide, flunisolide, fluocinonide, fluocinolone acetonide, 9-fluorocortisone, fluorohydroxyandrostenedione, fluorometholone, fluorometholone acetate, fluoxymesterone, flupredidene, fluprednisolone, flurandrenolide, formocortal, halcinonide, halometasone, halopredone, hyrcanoside, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone cypionate, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydrocortisone probutate, hydrocortisone valerate, 6-hydroxydexamethasone, isoflupredone, isoflupredone acetate, isoprednidene, meclorisone, methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, paramethasone, paramethasone acetate, prednisolone, prednisolone acetate, prednisolone metasulphobenzoate, prednisolone sodium phosphate, prednisolone tebutate, prednisolone-21-hemisuccinate free acid, prednisolone-21-acetate, prednisolone-21(beta-D-glucuronide), prednisone, prednylidene, procinonide, tralonide, triamcinolone, triamcinolone acetonide, triamcinolone acetonide 21-palmitate, triamcinolone diacetate, triamcinolone hexacetonide, or wortmannin.

3. The composition of claim 2 , wherein said corticosteroid is fludrocortisone, prednisolone, or prednisone.

4. The composition of claim 1 , wherein said composition is formulated for oral administration.

5. The composition of claim 1 , wherein said composition is formulated for topical administration.

6. The composition of claim 1 , wherein said composition is formulated for intravenous administration.

7. A pharmaceutical composition consisting of active ingredients and excipients, wherein said active ingredients consist of a corticosteroid and dipyridamole, and wherein said composition comprises 0.5 to 10 mg corticosteroid and 100 to 400 mg of dipyridamole, and wherein said dipyridamole enhances the potency of said corticosteroid.

8. The composition of claim 7 , wherein said corticosteroid is algestone, 6-alpha-fluoroprednisolone, 6-alpha-methylprednisolone, 6-alpha-methylprednisolone 21-acetate, 6-alpha-methylprednisolone 21-hemisuccinate sodium salt, 6-alpha,9-alpha-difluoroprednisolone 21-acetate 17-butyrate, amcinafal, beclomethasone, beclomethasone dipropionate, beclomethasone dipropionate monohydrate, 6-beta-hydroxycortisol, betamethasone, betamethasone-17-valerate, budesonide, clobetasol, clobetasol propionate, clobetasone, clocortolone, clocortolone pivalate, cortisone, cortisone acetate, cortodoxone, deflazacort, 21-deoxycortisol, deprodone, descinolone, desonide, desoximethasone, dexamethasone, dexamethasone-21-acetate, dichlorisone, diflorasone, diflorasone diacetate, diflucortolone, doxibetasol, fludrocortisone, flumethasone, flumethasone pivalate, flumoxonide, flunisolide, fluocinonide, fluocinolone acetonide, 9-fluorocortisone, fluorohydroxyandrostenedione, fluorometholone, fluorometholone acetate, fluoxymesterone, flupredidene, fluprednisolone, flurandrenolide, formocortal, halcinonide, halometasone, halopredone, hyrcanoside, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone cypionate, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydrocortisone probutate, hydrocortisone valerate, 6-hydroxydexamethasone, isoflupredone, isoflupredone acetate, isoprednidene, meclorisone, methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, paramethasone, paramethasone acetate, prednisolone, prednisolone acetate, prednisolone metasulphobenzoate, prednisolone sodium phosphate, prednisolone tebutate, prednisolone-21-hemisuccinate free acid, prednisolone-21-acetate, prednisolone-21(beta-D-glucuronide), prednisone, prednylidene, procinonide, tralonide, triamcinolone, triamcinolone acetonide, triamcinolone acetonide 21-palmitate, triamcinolone diacetate, triamcinolone hexacetonide, or wortmannin.

9. The composition of claim 8 , wherein said corticosteroid is fludrocortisone, prednisolone, or prednisone.

10. The composition of claim 7 , wherein said composition is formulated for oral administration.

11. The composition of claim 7 , wherein said composition is formulated for topical administration.

12. The composition of claim 7 , wherein said composition is formulated for intravenous administration.

13. A composition formulated for oral administration comprising only two active ingredients, wherein the first of said active ingredients is dipyridamole in an amount that ranges from 100 to 400 mg and the second of said active ingredients is prednisolone in an amount that ranges from 0.5 to 10 mg, wherein said dipyridamole enhances the potency of said prednisolone.

Assignments (2)
CHANGE OF NAME Recorded Oct 15, 2010
From: COMBINATORX, INCORPORATED
To: ZALICUS INC.
Reel/Frame 025150/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2006
From: KEITH, CURTIS; BORISY, ALEXIS; ZIMMERMANN, GRANT; JOST-PRICE, EDWARD ROYDON; MANIVASAKAM, PALANIYANDI; HURST, NICOLE W.; FOLEY, MICHAEL A.
To: COMBINATORX, INC.
Reel/Frame 018572/0788 →
Continuity (3)
Division 10264991 · Oct 4, 2002
Provisional Application 60327674 · Oct 5, 2001
Related Publication 20060234991A1 · Oct 19, 2006